1 / 7

Industry Symposium

World Congress Tissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5-8, 2012. Industry Symposium. Organized by TERMIS-AM and TERMIS-EU Industry Committees. TERMIS-AM Industry Committee. Established 2009 Mission

polly
Download Presentation

Industry Symposium

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. World CongressTissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5-8, 2012 Industry Symposium Organized by TERMIS-AM and TERMIS-EU Industry Committees

  2. TERMIS-AM Industry Committee • Established 2009 • Mission • Support commercialization in Tissue Engineering/Regenerative Medicine (TE/RM) • Goals • Define and address obstacles/hurdles to product commercialization • Promote collaborations to build a viable TE/RM industry • Members • Kiki B. Hellman, PhD; The Hellman Group. LLC; Chair • Timothy A. Bertram, DMV, PhD; Tengion • Peter C. Johnson, MD; Avery Dennison • Mark Van Dyke, PhD; Wake Forest University Health Sciences • Bill Tawil, PhD; Baxter Biosurgery

  3. TERMIS-EU Industry Committee • Established 2011 • Mission • Motivate translation of academic research into commercial products, in Tissue Engineering/Regenerative Medicine (TE/RM) • Connect the scientific & clinical communities with TE/RM industries • Goals • Give answers to critical questions, paving the road of TE/RM commercial translation, by key stakeholders, from past experiences • Promoteacademia–industry meetings & partnerships for more effective commercial translation in TE/RM • Members • Yves Bayon, PhD;Covidien – Sofradim Production; Chair • Simon Ellison, MBA; NHS Blood & Transplant • John Barry, PhD; Baxter Innovations • Paul Stroemer, PhD, Reneuron • Chris Mason, PhD; University College of London • Alain Vertes, PhD; London Business School Sloan Fellow

  4. World CongressTERMIS • Industry Symposium Partnership, the key for successful translation of Regenerative Products Organized by TERMIS-AM and TERMIS-EU Industry Committees

  5. World CongressTissue Engineering and Regenerative Medicine International Society Vienna, Austria September 5-8, 2012 Industry Symposium SESSION 1: “Commercialization of Regenerative Products: The Academe/Industry Partnership” Organized by TERMIS-AM and TERMIS-EU Industry Committees

  6. Commercialization of Regenerative Products: The Academe/Industry Partnership Organizers: TERMIS-AM & TERMIS-EU Industry Committees Main Goals: • to learn from past academia-industry collaborative experiences in TE/RM commercial development • to enableacademia and industry to understand how best to work together and identify individual collaborations that can rapidly move forward.

  7. Commercialization of Regenerative Products: The Academe/Industry Partnership 9:05 – 9:20 Vienna/Austria - From a Strong Biomedical Tradition to a Future of Innovation and Patient Care Ehrlich H, Baxter Bioscience, Austria 9:20 – 9:40 Commercialization of regenerative medicine products: the academia-industry partnership Vertès A, London Business School, Sloan Fellowship, UK 9:40 – 10:00 Commercializing regenerative medicine therapeutics and sustaining a successful business Arshad A, Scientia Advisors, USA 10:00 – 10:15 Translating academic concepts to commercial medical products: A complex academic, industrial partnership Coury A, Consultant, USA 10:15 – 10:30 Successful translation of academic research using combinations of mesenchymalstromal cells with pharmaceutical agents for clinical applications in regenerative medicine Ghosh P, Mesoblast Ltd, Australia

More Related